Avatar
New York Post News source @nypost.com · New York City 🇺🇸· 4w

#ObesityTreatment #EyeHealth #GLP1Agonists

Link Preview
nypost.com
Which GLP-1 drug has the highest risk of sudden sight loss and 'eye...
The results of this obesity medication are literally eye-popping. A new review of adverse effects reports to the FDA between the years 2017 and 2024 reveals that Ozempic and Wegovy have both been linked to dozens of cases of ischemic optic neuropathy (ION), or sudden vision loss caused by restricted blood flow to the optic nerve.
Avatar
Newsweek News source @newsweek.com · New York 🇺🇸· 4w

#SugaryDrinks #ObesityCrisis #PublicHealth

Link Preview
www.newsweek.com
Democrats and Republicans flip sides in war on sugary drinks
For decades, the debate over what Americans should drink was considered settled politics. Republicans defended personal choice.
H

#CardiovascularHealth #ObesityManagement #GLP1

Link Preview
health.usnews.com
GLP-1 Drugs for Heart Health: Benefits, Side Effects & Who Should Take Them
Cardiologists and obesity medicine physicians alike are hopeful about these preliminary findings. However, lifestyle habits, including getting adequate sleep, eating healthy and exercising, are still the top ways to stave off cardiovascular disease.
W
The Wall Street Journal News source @wsj.com · New York City 🇺🇸· Feb 25

#ObesityTreatment #PharmaceuticalNews #ClinicalTrials

Link Preview
www.wsj.com
Novo Nordisk, United Laboratories Say New Obesity Drug Helps Patients Lose Weight in Trial
Novo Nordisk and United Biotechnology's experimental obesity drug UBT251 achieved up to 19. 7% mean weight loss in a midstage China trial.
N

#Obesity #Inflammation #HealthResearch

Link Preview
www.nih.gov
Understanding obesity-induced inflammation
More than one-third of American adults live with obesity. Obesity causes inflammation throughout the body, contributing to many of its health consequences.
Avatar
Yahoo News source @yahoo.com · Sunnyvale, California 🇺🇸· Feb 24

#ObesityTreatment #WeightLoss #FDAApproval

Link Preview
www.yahoo.com
FDA approves Allurion's PMA application for Gastric Balloon System
Allurion's founder and CEO Dr Shantanu Gaur stated that the Smart Capsule offers a safe and effective alternative to GLP-1s and bariatric surgery, aiming to provide metabolically healthy weight loss and become a standard tool in obesity treatment in the US.
Avatar
CNBC News source @cnbc.com · New Jersey 🇺🇸· Feb 23

#EliLilly #Zepbound #ObesityTreatment

Link Preview
www.cnbc.com
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024. Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen.
Avatar
Forbes News source @forbes.com · Jersey City, New Jersey 🇯🇪· Feb 14

#Obesity #HealthInnovation #PersonalizedMedicine

Link Preview
www.forbes.com
How GLP-1 Weight Loss Drugs Have Revolutionized Obesity- Lessons Learned
The blockbuster weight loss GLP-1 drugs such as Wegovy and Zepbound have revolutionized obesity, the way healthcare workers and patients think about the disease and the way it is treated.
Avatar
Harvard Gazette News source @news.harvard.edu · Feb 13

#HealthInsurance #GLP1 #ObesityTreatment

Link Preview
news.harvard.edu
Pricey blockbuster GLP-1s are costing users -- and most of the rest of us, too -- Harvard Gazette
Health insurers are passing along cost for coverage in form of higher rates across the board, policy researcher says The popularity of pricey GLP-1 drugs has hit the budgets of users -- and just about everyone else.
Avatar
Forbes News source @forbes.com · Jersey City, New Jersey 🇯🇪· Feb 11

#Obesity #HealthEquity #Medicaid

Link Preview
www.forbes.com
Ending Medicaid Coverage For GLP-1 Drugs Deepens Divide In Chronic Care
GLP-1 weight loss drugs didn't create health inequities -- but Medicaid cuts may deepen them. The question now facing the U.
Avatar
Fox News News source @foxnews.com · New York City 🇺🇸· Feb 11

#Health #Nutrition #Obesity

Link Preview
www.foxnews.com
Mike Tyson in the 'fight of my life' as he partners with Trump admin in health initiative to tackle obesity
Boxing legend Mike Tyson said that he wants to be a "hero" for those fighting obesity. Legendary boxer Mike Tyson found himself in a new arena on Wednesday as he stood with Health and Human Services (HHS) Secretary Robert F.
Avatar
ABC News News source @abcnews.go.com · New York City 🗽· Jan 29

#Obesity #PublicHealth #Nutrition

Link Preview
abcnews.go.com
Obesity to rise by 19 million and affect 126 million American adults by 2035, new study finds
Researchers reviewed the body mass index of over 11 million Americans. The number of Americans living with obesity is expected to rise by 19 million and affect nearly 126 million people by 2035, according to a new study published in the Journal of the American Medical Association on Wednesday.
Avatar
Yahoo! News source @ca.style.yahoo.com · Sunnyvale, California 🇺🇸· Jan 28

#CardiovascularHealth #ObesityTrends #YoungAdultsHealth

Link Preview
ca.style.yahoo.com
Heart health is improving overall. So why are strokes rising among young adults?
Add Yahoo as a preferred source to see more of our stories on Google. By some measures, young adults in the U. S. are healthier -- or at least more health-conscious, judging by their spending on wellness goods and services, as well as social media posts -- than previous generations.
Avatar
New York Post News source @nypost.com · New York City 🇺🇸· Jan 28

#Obesity #PublicHealth #ChronicConditions

Link Preview
nypost.com
Ozempic who? Nearly half of American adults will be obese by 2035:...
America's obesity problem is tipping the scales. A new study found that the share of US adults living with obesity has more than doubled over the past three decades, ballooning from 19% in 1990 to 42% in 2022.
W
The Wall Street Journal News source @wsj.com · New York City 🇺🇸· Jan 28

#WeightLoss #ObesityManagement #GLP1Medications

Link Preview
www.wsj.com
Here's What Happens When You Stop Taking Ozempic and Wegovy
Studies show that after stopping the drugs, people typically regain lost weight within about 1. 5 years. Peter Dazeley/Getty Images A recent email ad from a telehealth company selling weight-loss medications features tennis-superstar Serena Williams.
U
USA Today News source @usatoday.com · McLean, Virginia 🇺🇸· Jan 26

#Obesity #WeightLoss #HealthEducation

Link Preview
www.usatoday.com
Wegovy works - at first. That won't end our obesity problem. | Opinion
According to a major UNICEF study, roughly one in 10 children aged between five and 19 years old are believed to be affected by obesity.
Avatar
New York Post News source @nypost.com · New York City 🇺🇸· Jan 25

#FoodAddiction #ObesityCrisis #PublicHealth

Link Preview
nypost.com
RFK Jr. blames Big Tobacco for addictive food that has Americans...
Health and Human Secretary Robert Kennedy Jr. blamed the major tobacco companies for manufacturing bad, ultra-processed addictive food that has fueled obesity, chronic disease and even "poisoned" Americans.
Avatar
CBS News News source @cbsnews.com · New York 🇺🇸· Jan 5

#WeightLoss #HealthInnovation #ObesityTreatment

Link Preview
www.cbsnews.com
Novo Nordisk debuts Wegovy weight-loss pill in the U.S.
Mary Cunningham is a reporter for CBS MoneyWatch. She previously worked at "60 Minutes," CBSNews. com and CBS News 24/7 as part of the CBS News Associate Program.
Avatar
Daily Voice News source @dailyvoice.com · Jan 5

#ObesityTreatment #GLP1 #WeightLossMedication

Link Preview
dailyvoice.com
First GLP-1 Weight-Loss Pill Hits Pharmacies: How Much It Costs, What To Know
The first oral glucagon-like peptide-1 (GLP-1) drug has launched nationwide, marking a major expansion of access to the popular treatments credited with reshaping obesity care in the US.
Avatar
Daily Voice News source @dailyvoice.com · Jan 5

#ObesityTreatment #GLP1 #WeightLossMedication

Link Preview
dailyvoice.com
First GLP-1 Weight-Loss Pill Hits Pharmacies: How Much It Costs, What To Know
The first oral glucagon-like peptide-1 (GLP-1) drug has launched nationwide, marking a major expansion of access to the popular treatments credited with reshaping obesity care in the US.